The use of antimalarial drugs: report of a WHO informal consultation

Policy implications:

Current status of antimalarial drug resistance:

development of resistance.

Assessment of antimalarial drug susceptibility.

Plasmodium falciparum resistance.

Plasmodium vivax resistance.

Combination Therapy:

Rationale for the use of combination therapy.

Artemisinin - based combination therapy.

Implementation of combination therapy - operational isues.

Chemoprophylaxis and treatment of malaria in special groups:

Chemoprophylaxis and intermittent treatment of malaria in pregnancy.

Chemoprophylaxis and stand-by treatment in travellers.

Management of severe malaria.

Vivax malaria.

Formulations for paediatric use.

Antimalarial treatment policies:

Definition.

Purpose.

Development.

Factors influencing antimalarial treatment policies.

Health-seeking behavior

Criteria for changing treatment poicy

Process of changing treatment policy - country examples

Implementation and access to antimalarial drugs in endemic countries

Antimalarial drugs for malaria prevention and treatment

Chloroquince

Amodiaquine

Antifolate drugs sulfa drug - pyrimethamine combinations

Proguanil.

Mefloquine

Quinine, quinidine and related alkaloids

Halofantrine

Artemisinin and its derivatives

Primaquine

Antibiotics used as antimalarial drugs

Atovaquone-proguanil

Chloroquine-proguanil

Artemether - lumefantrine

Mefloquine-sulfadoxine - pyrimethamine

Status and potential of combination therapies

Past or present co-administered non fixed combinations

Combinations undergoing consideration or trial

Potential combinations under consideration or trial with not yet available drugs

Guidance on the selection of drugs for national antimalarial treatment policies

Common antimalarial drugs that should be considered in drug selection

Inglés